Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients
On February 8, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Camargo Pharmaceutical Services. This collaboration aims to prepare and submit an Investigational New Drug (IND) application for their topical product, HT-001, to the U.S. FDA. The IND is anticipated to receive feedback by February 22, 2021, as Hoth conducts GLP toxicology studies. HT-001 targets skin disorders related to epidermal growth factor receptor inhibitors. The company aims to expedite the NDA submission process through a 505(b)(2) development pathway.
- Agreement with Camargo Pharmaceutical Services to facilitate IND submission.
- HT-001 is positioned to target unmet medical needs in cancer treatment.
- FDA feedback on IND application expected soon, potentially expediting clinical trials.
- None.
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for HT-001 topical product to the U.S. Food and Drug Administration for initiating the first clinical trial.
Camargo partners with emerging biopharma companies to address unmet medical needs in rare and complex areas by optimizing the path to patients. The Company will write, prepare, and submit an IND in the electronic Common Technical Document (eCTD) format to the US FDA. Initiation of the IND is in anticipation of FDA feedback expected for HT-001 from the Pre-IND meeting responses expected February 22, 2021 and the GLP toxicology studies in process.
HT-001 is a topical product being developed for the treatment of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor (EGFR) inhibitor therapy. Currently in the preclinical stage of development of HT-001, the product is being positioned for NDA submission via the 505(b)(2) development pathway, in which Hoth Therapeutics intends to rely on information not obtained through right of reference in order to reduce the nonclinical and clinical program and expedite time to NDA submission.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are pleased to be progressing through the federal approval process for initiation of clinical trials of our proprietary topical dermatological treatment."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-partners-with-camargo-pharmaceutical-services-for-the-ht-001-ind-a-treatment-for-cancer-patients-301224190.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is Hoth Therapeutics planning with the HT-001 product?
When is the FDA feedback for HT-001 expected?
How does Hoth Therapeutics intend to expedite the NDA submission for HT-001?
What medical condition is HT-001 targeting?
Which company is partnering with Hoth Therapeutics for HT-001?
